Clik here to view.
MedTech Innovator Asia Pacific Names APrevent Top 2024 Innovator in Grand...
LOS ANGELES & SINGAPORE MedTech Innovator, the largest accelerator of medical technology companies in the world, in partnership with Asia Pacific Medical Technology Association (APACMed), the...
View ArticleClik here to view.
BeiGene Announces Updates to Commercial Leadership Team
SAN MATEO, Calif. BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the appointment of Matt Shaulis as General Manager of North America, effective...
View ArticleClik here to view.
Datopotamab Deruxtecan Showed Median Overall Survival of 14.6 Months in...
TOKYO & BASKING RIDGE, N.J. Detailed results from the TROPION-Lung01 phase 3 trial showed a clinically meaningful trend toward improving overall survival (OS) with datopotamab deruxtecan...
View ArticleClik here to view.
ZTI Biosciences Engages EF Hutton as Strategic and Financial Advisor
DAEJEON, South Korea ZTI Biosciences Co., Ltd. (“ZTI Biosciences” or “ZTI”), a radiopharmaceutical developer for cancer therapy based on nanomaterial technology, today announced that it has entered...
View ArticleClik here to view.
Delta-Fly Pharma Inc.: Phase I/II Combo-study of DFP-10917 with Venetoclax in...
TOKUSHIMA, Japan Following to the previous information on April 8th. 2024, we are excited to share our latest development status. A Phase I/II clinical trial of DFP-10917 in combination with...
View ArticleClik here to view.
Avistone Announces Results from a Sponsored Clinical Research Program...
BEIJING Beijing Avistone Biotechnology Co., Ltd. (also referred to as Avistone Biotechnology or Avistone), an innovative biotechnology company focused on precision oncology therapeutics, announced...
View ArticleClik here to view.
Merck Announces Positive Top-line Results from Phase 3 Trial Evaluating...
RAHWAY, N.J. Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive top-line results from its pivotal Phase 3 trial (V503-064) evaluating the company’s...
View ArticleClik here to view.
ITM Obtains Exclusive Worldwide License from Debiopharm for CA IX-Targeted...
MUNICH & GARCHING, Germany & LAUSANNE, Switzerland ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company and Debiopharm (www.debiopharm.com), a Swiss-based,...
View ArticleClik here to view.
ENHERTU® Showed Substantial Clinical Activity in Patients with HER2 Positive...
TOKYO & BASKING RIDGE, N.J. Results from the DESTINY-Breast12 phase 3b/4 trial showed that ENHERTU® (trastuzumab deruxtecan) demonstrated substantial overall and intracranial clinical activity...
View ArticleClik here to view.
Latest Data of InnoCare’s Orelabrutinib Presented at the European Society for...
BEIJING Latest data of InnoCare’s (HKEX: 09969; SSE: 688428) orelabrutinib were presented at the European Society for Medical Oncology (ESMO) Congress 2024. Oral Presentation A Prospective Study of...
View ArticleClik here to view.
First of its Kind Colorectal Cancer Data from Prospective GALAXY Study...
AUSTIN, Texas Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, announced that new data from the GALAXY arm of the ongoing CIRCULATE-Japan trial was released today...
View ArticleClik here to view.
DS-9606 Shows Promising Preliminary Clinical Activity in Patients with...
TOKYO & BASKING RIDGE, N.J. Initial results from dose escalation in the first-in-human phase 1 trial of DS-9606 suggest early promising clinical activity in patients with advanced solid tumors...
View ArticleClik here to view.
Data from a Phase 1 Trial of HighField Biopharmaceuticals’ HF1K16 Show the...
HANGZHOU, China HighField Biopharmaceuticals, a clinical stage company using lipid-based therapeutics to treat cancer, diabetes and other diseases, announced today its CEO and Scientific Founder...
View ArticleClik here to view.
GC Aesthetics® Launches YOUTHLY™: A New Era for Breast Implants in China
DUBLIN GC Aesthetics® (GCA), a leading medical technology company committed to advancing women’s health through innovative aesthetic and reconstructive breast solutions, is excited to announce the...
View ArticleClik here to view.
Zai Lab to Present Preclinical Data of ZL-1503, an IL-13/IL-31 Bispecific...
SHANGHAI & CAMBRIDGE, Mass. Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688; “Zai Lab”) today announced that data from a preclinical study of ZL-1503, the company’s internally discovered IL-13/IL-31...
View ArticleClik here to view.
GOZILA Study Published in Nature Medicine Shows Patients With Advanced Cancer...
PALO ALTO, Calif. Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the peer-reviewed journal Nature Medicine published results from the SCRUM-Japan GOZILA...
View ArticleClik here to view.
InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for...
BEIJING InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the approval of the...
View ArticleClik here to view.
GC Aesthetics®推出YOUTHLY™：中国乳房植体进入新时代
都柏林 (美国商业资讯)– GC Aesthetics® (GCA)是一家领先的医疗技术公司，致力于通过创新的乳房美容和再造解决方案提升女性健康水平。他们很高兴地宣布在中国推出YOUTHLY™品牌，该品牌的特色在于其最新的乳房植体创新成果：PERLE™、Luna XT™和The Round Collection™（100%填充）的最新版本。 通过与G&S...
View ArticleClik here to view.
Datopotamab Deruxtecan Final Overall Survival Results Reported in Patients...
TOKYO & BASKING RIDGE, N.J. Topline results from the TROPION-Breast01 phase 3 trial of datopotamab deruxtecan (Dato-DXd) compared to investigator’s choice of chemotherapy, which previously met...
View ArticleClik here to view.
Debiopharm Recognizes Groundbreaking Japanese Cancer Research During the 83rd...
LAUSANNE, Switzerland Debiopharm (www.debiopharm.com), a Swiss-based, global biopharmaceutical company, aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases, today...
View Article